We can’t show the full text here under this license. Use the link below to read it at the source.
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)
How Starting Finerenone and Empagliflozin Together Affects Kidney Protein Levels and Safety in Type 2 Diabetes and Kidney Disease, Depending on Prior Use of GLP-1 Receptor Agonists
AI simplified
Abstract
Among 800 participants, 23% used a GLP-1 receptor agonist at baseline, showing a 51% reduction in urinary albumin-to-creatinine ratio with combination therapy at day 180.
- Combination therapy with finerenone and an SGLT2 inhibitor led to a greater reduction in urinary albumin-to-creatinine ratio compared to either drug alone.
- Participants using a GLP-1 receptor agonist experienced a 51% reduction in urinary albumin-to-creatinine ratio with combination therapy.
- Those not using a GLP-1 receptor agonist had a 56% reduction with combination therapy.
- Hyperkalemia incidence rates were similar between participants with and without baseline GLP-1 receptor agonist use, at 9.0% and 9.5%, respectively.
- Changes in estimated glomerular filtration rate were consistent regardless of GLP-1 receptor agonist use, and acute kidney injury was rare.
- Decreases in systolic blood pressure were observed and were more pronounced with combination therapy.
AI simplified